Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Spain’s Industrial Output Records Steady Growth in October Amid Revised September Figures 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Australia’s Economic Growth Slows in Q3 Despite Strong Investment Activity 
Appeals Court Blocks Expansion of Fast-Track Deportations in the U.S. 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
RBI Cuts Repo Rate to 5.25% as Inflation Cools and Growth Outlook Strengthens 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
The US Food and Drug Administration (FDA) is planning to regulate the use of the cannabis compound CBD in food and supplements after weighing the evidence on the compound's safety.
The FDA will decide whether regulating legal cannabis will require new agency rules or new legislation from Congress.
Cannabis products, excluding Epidiolex, are illegal at the federal level in the US, although some states allow their use.
According to Patrick Cournoyer, who heads the FDA office developing the agency's cannabis strategy, the FDA will ascertain if CBD can be safely eaten every day for a long period or during pregnancy amid concerns about future fertility.
.
